Vimal Kumar Derebail MD MPH FASN

Nephrology•Chapel Hill, NC

Glomerular Disease

Associate Professor of Medicine University of North Carolina at Chapel Hill School of Medicine

Join to View Full Profile

7024 Burnett Womack Campus# 7155Chapel Hill, NC 27599
Phone+1 919-966-2561
Fax+1 919-966-4251

Education & Training

University of North Carolina HospitalsFellowship, Research Fellow in Nephrology, 2009 - 2011
University of North Carolina at Chapel Hill, Gillings School of Global Public HealthMPH, Epidemiology, 2007 - 2010
University of North Carolina HospitalsFellowship, Nephrology, 2006 - 2009
University of North Carolina HospitalsResidency, Internal Medicine, 2002 - 2005
Medical College of Georgia at Augusta UniversityClass of 2002, MD
Duke UniversityBS, Biology / Religion, 1993 - 1997

Certifications & Licensure

NC State Medical License 2002 - 2025
SC State Medical License 2021 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Nephrology

Clinical Trials

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients Start of enrollment: 2011 Aug 01
Completed
Phase 4
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
COMPLETED
PHASE2
Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome Start of enrollment: 2012 May 01
Completed
Phase 1
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease Start of enrollment: 2014 May 01
Completed
Phase 3
Pharmacokinetics of Apixaban in Nephrotic Syndrome Start of enrollment: 2017 Apr 30
Completed
Phase 1
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation Start of enrollment: 2016 Dec 01
Completed
Phase 4
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Start of enrollment: 2017 Mar 15
COMPLETED
PHASE3
Kidney Function in Sickle Cell Anemia Start of enrollment: 2017 Nov 17
ACTIVE_NOT_RECRUITING
Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN) Start of enrollment: 2017 Oct 06
Completed
Phase 2
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) Start of enrollment: 2018 Apr 17
ACTIVE_NOT_RECRUITING
PHASE3
Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA Start of enrollment: 2018 Oct 15
Terminated
Phase 2
ADPKD Alterations in Hepatic Transporter Function Start of enrollment: 2018 Sep 17
Completed
Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis Start of enrollment: 2019 Jun 28
Suspended
Not Applicable
Belimumab With Rituximab for Primary Membranous Nephropathy Start of enrollment: 2020 Mar 06
RECRUITING
PHASE2
A Study With Imlifidase in Anti-GBM Disease Start of enrollment: 2022 Dec 22
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

Addressing the Pathophysiology of Venous Thrombosis and Chronic Kidney Disease in Sickle Cell Trait Using a Mouse Model.
Fatima Trebak, Mohammad Sako, Steven P Grover, Karnsasin Seanoon, Izabela J Pawlinski
Blood Advances. 2025-03-14
The evolving landscape of vasculitis management: past, current and emerging.
Ronald J Falk, Meghan E Free, Dominic J Ciavatta, Dhruti P Chen, Vimal K Derebail
Rheumatology. 2025-03-01
Sequential carbonyl derivatives and hydrazone adduct formation on myeloperoxidase contribute to development of ANCA-vasculitis.
Gang Xi, Elizabeth A Mclnnis, Olivier Lardinois, Peiqi Hu, John S Poulton
The Journal of Clinical Investigation. 2025-02-27

Journal Articles

Effect of Renin‐Angiotensin‐Aldosterone System Blocking Agents on Progression of Glomerulopathy in Sickle Cell Disease
Vimal K Derebail, Kenneth I Ataga, British Journal of Haematology
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS
Howard Trachtman, Peter Nelson, Abanti Chaudhuri, Jai Radhakrishnan, Olga Zhdanova, Debbie S Gipson, Tarak Srivastava, Kenneth Lieberman, Vimal Kumar Derebail, Jonatha..., Journal of the American Society of Nephrology

Abstracts/Posters

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomize...
Vimal K. Derebail, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Opioid Analgesics Are Associated with Albuminuria in Adult Patients with Sickle Cell Anemia
Vimal K. Derebail, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Manifestations of Reduced Kidney Function Occur at a Higher Estimated Glomerular Filtration Rate in Sickle Cell Anemia
Vimal K. Derebail, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Manifestations of Reduced Kidney Function Occur at a Higher Estimated Glomerular Filtration Rate in Sickle Cell Anemia
Vimal K. Derebail, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Association of Sickle Cell Trait with Measures of Cognitive Function and Dementia in African Americans
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Rapid Decline in Kidney Function in Sickle Cell Disease
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Sickle Cell Trait Is Not Risk Factor for Kidney Disease: Study Contradicts Earlier FindingsSeptember 14th, 2011
Sickle Cell Trait in African-American Dialysis Patients Affects Dosing of Anemia DrugsFebruary 10th, 2016